SFAM
COGT icon

Springhill Fund Asset Management’s Cogent Biosciences COGT Stock Holding History

Springhill Fund Asset Management’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-29,491
Closed -$177K – 5
2025
Q1 		$177K Sell
29,491
-519,063
-95% -$4.07M 0.85% 19
2024
Q4 		$4.28M Buy
+548,554
New +$5.47M 6.95% 7

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Springhill Fund Asset Management's COGT Position: Q2 2025 in Review

Springhill Fund Asset Management sold out of Cogent Biosciences (COGT) in Q2 2025, closing a stake of 29,491 shares — an estimated $177K sold.

Springhill Fund Asset Management first reported a position in COGT in Q4 2024 and held it in 2 quarters. The position peaked at $4.28M in Q4 2024. 180 funds tracked by Wall St. Rank hold COGT as of Q2 2025.

  • Springhill Fund Asset Management reported no remaining Cogent Biosciences position as of Q2 2025 after selling out during the quarter.
  • Springhill Fund Asset Management sold 29,491 Cogent Biosciences shares in Q2 2025, an estimated $177K.
  • Springhill Fund Asset Management first reported a position in Cogent Biosciences in Q4 2024 and held it in 2 quarters.
  • Springhill Fund Asset Management's Cogent Biosciences position peaked at $4.28M in Q4 2024.
  • 180 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2025.

Based on Springhill Fund Asset Management's 13F filing for Q2 2025.